Seattle Genetics | SGEN - Stock


Seattle Genetics reported $531.19M in Stock for its fiscal quarter ending in September of 2023.



Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Astellas Pharma JPY 297.26B 9.92B Mar/2025
Bayer EUR 12.34B 3M Dec/2025
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Eisai JPY 236.46B 9.14B Sep/2025
Eli Lilly USD 14.53B 785M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Exelixis USD 26.6M 4.92M Mar/2026
Genmab DKK 13M 1000K Jun/2025
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 115.62M 14.56M Mar/2026
Insmed USD 132.91M 841K Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.29B 17M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Takeda JPY 1.41T 107.71B Dec/2025
Teva Pharmaceutical Industries USD 3.18B 144M Dec/2025
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026